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Abstract
Type-D personality is characterized by the stable traits of negative
affectivity and social inhibition. In recent years, a body of studies has examined
the relationship between the presence of Type-D personality and prognosis in
cardiovascular patient populations. The present meta-analysis, investigated
relationships between Type-D personality and three different outcome
measures: major adverse cardiac events, quality of life, and biochemical markers
of disease. A random effects meta-analytic model was utilized to calculate
omnibus effect sizes for each set of related studies. Tests of homogeneity were
conducted, and all studies were coded for the presence of potential moderators.
A total of 14 studies were included in the meta-analysis, and one effect size was
calculated in the major adverse cardiac event analysis, two were calculated in
the quality of life analysis and seven effect sizes were calculated for the
biochemical marker analysis. An association was found between Type-D
personality and major adverse cardiac events, one measure of quality of life,
interleukin-6 levels and tumor necrosis factor-alpha soluble receptor levels. No
association was found with respect to cortisol or tumor necrosis factor-alpha
levels. All other effect sizes trended towards significance. It is suggested that a
broader body of research be conducted in this area in order to generalize these
associations. Research is also warranted to investigate the effects of treatment
with a focus on alleviating emotional distress on Type-D individuals in order to
identify options to improve prognosis in this high-risk patient group.
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Introduction
Since the relatively recent proposal of the Type-D (distressed) personality
construct, there has been an abundance of research investigating the relations
between Type-D personality and various psychological and somatic symptoms.
Type-D personality is the combination of two stable personality constructs:
negative affectivity and social inhibition. Negative affectivity is the tendency to
consistently experience negative emotions regardless of the time or situation
whereas social inhibition is the stable tendency to inhibit the expression of these
emotions, experience high levels of insecurity in social situations and act closedoff or reserved for fear of disapproval by others (Denollet, 1998; Denollet, Vaes,
& Brutsaert, 2000). Whereas negative affectivity and social inhibition
independently have been demonstrated to have detrimental effects on cardiac
prognosis, it is their interaction as manifest in the Type-D personality that has
been shown in individual studies to be predictive of major adverse cardiac
events (MACE) which include death, myocardial infarction, percutaneous
coronary intervention and coronary artery bypass grafting surgery (Denollet et
al., 2006).
Type-D personality has also been demonstrated to be a stable taxonomy in
acute myocardial infarction patients who were assessed for Type-D personality,
depression and anxiety at multiple time points over an 18-month period.
Variability in mood status and disease severity did not have an association with
Type-D personality diagnosis (Martens, Kupper, Pederson, Aquarius, & Denollet,
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2007). Issues concerning the similarities and differences between Type-D and
depression have also been addressed. However, in further examination by
Denollet and colleagues of whether Type-D personality and depression are
different forms of emotional distress, it was found that Type-D personality is not
due to co-morbid depression as only 25% of their total sample of 340 cardiac
patients exhibited both depression and Type-D personality whereas the other
75% were diagnosed with either Type-D personality or depression. This study
also concluded that Type-D personality cannot be assumed from a diagnosis of
depression and that the findings support the validity of the two forms of distress
as separate constructs; depression being a disorder that lacks the trait of social
inhibition and Type-D being a stable personality construct including both the
personality traits of negative affectivity and social inhibition (Denollet et al,
2009).
The individual constructs which constitute Type-D personality have also been
assessed individually to determine their relationship with cardiac prognosis. In a
2006 study, Denollet and colleagues assessed the role which social inhibition
plays with respect to the role of negative emotions’ effect on cardiac prognosis
(Denollet et al., 2006). A total of 875 subjects were assessed on separate scales
of negative affectivity and social inhibition six months post percutaneous
coronary intervention. It was found that patients with high levels of negative
affectivity and social inhibition were more likely to experience MACE than
patients who were only classified as having high levels of negative affectivity.
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This suggests that it is the interaction between negative affectivity and social
inhibition, which together constitute Type-D personality, and not merely the
presence of one trait or the other, which may account for poor cardiac
prognosis.
Previous research found links between Type-D personality and multiple
predictors of poor prognosis in cardiac patients. Type-D is a predictor of clinically
significant and chronic anxiety in chronic heart failure and percutaneous
coronary intervention patients at one year follow up (Schiffer, Pederson, Broers,
Widdershoven, & Denollet, 2008; van Gestel et al., 2007; Spindler, Pederson,
Serruys, Erdman, & van Domburg, 2007) and elevated anxiety levels in
implantable cardioverter defibrillator patients (Pederson, van Domburg, Theuns,
Jordaens, & Wedman 2004). Another risk factor for increased morbidity that has
been linked to Type-D personality is vital exhaustion (Kop, 1997; Kop, 1999). In a
sample of 171 patients with ischemic heart disease, patients who were identified
as having Type-D personality scored higher on assessments of vital exhaustion
independent of other variables (Pederson & Middel, 2001). Type-D personality
has also been shown to have a relationship with vital exhaustion in percutaneous
coronary intervention patients over the course of one year with Type-D patients
consistently scoring higher on vital exhaustion assessments than non Type-D
patients (Pederson, Daemen, & van de Sande, 2007). Both vital exhaustion and
Type-D personality are independently associated with inadequate heart rate
recovery, another predictor of morbidity and mortality, in chronic heart failure
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patients (von Kanel et al, 2009). Epithelial progenitor cells, necessary for the
repair of damage to the body including vascular damage, are reduced by 54% in
Type-D chronic heart failure patients as compared to non Type-D patients
(Craenenbroeck, Denollet, Paelinck, & Conraads, 2009). Type-D personality has
also been linked with low levels of health related behaviors and reduced levels of
social support which are associated with a negative impact on cardiac outcomes
(Williams et al, 2008). Social support sublevels of structural support (social
networking and frequency of contact) and functional support (received and
perceived social support) have reliably been connected to cardiac death as well
as mortality from other causes (Rozanski, Blumenthal, Davidson, Saab, &
Kubzansky, 2005). In research pertaining to potential disease pathways, it has
been found that cardiac patients with Type-D personality may experience
prolonged disruption of the hypothalamic-pituitary-adrenal axis after acute
coronary events resulting in increased cortisol output during the day (Molloy,
Perkins-Porras, Strike, & Steptoe, 2008).
Type-D personality has also been found to have predictive power for noncardiac populations as well. A recent review from the Center of Research on
Psychology in Somatic Diseases in Tilburg, Netherlands detailed the associations
between Type-D personality and disease in non-cardiac populations.
Correlations were found between the presence of Type-D personality and poor
performance as well as increased cognitive complaints following traumatic brain
injury, increased side effects of and poor adherence to treatment of sleep apnea,

5

poor health related quality of life and increased disease related distress in
tinnitus patients, poor mental quality of life in diabetic foot syndrome patients,
increased depression and anxiety in chronic pain patients, greater emotional and
physical disability in peripheral vestibular patients and among melanoma
survivors it was associated with subpar health status as well as a more
prominent negative impact of cancer on the patients’ lives. In the primary care
setting, patients with Type-D personality have been documented as experiencing
elevated rates of comorbidity, poor personal evaluations of perceived health
status and poor physical as well as inadequate psychosocial functioning. In
studies assessing the prevalence of Type-D personality among patient groups,
higher prevalence was found in vulvovaginal candidiasis and tinnitus patient
groups (Mols & Denollet, 2010).
Quality of Life
Health-related quality of life encompasses the assessment of three
different domains: biological functioning, psychological functioning and social
functioning. Health status, functional status and quality of life are all terms used
to describe the same essential construct. The broad dimensions that are
included in assessment of health-related quality of life allow for assessment of
the degree of impairment of cherished aspects of life that are not considered
traditional health measurements but may be associated with adverse health
such as autonomy, ability to work, income and environmental quality. This
measurement takes into account not only the physiologic measures most often
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relied upon by physicians but other aspects of life which are impacted by chronic
disease as well. It is only recently that quality of life has gained attention as a
means to provide clinicians with a more complete picture of patient health
beyond purely physiological measures such as cholesterol levels or outcome
measures such as mortality. Its relevance also extends to examine the effects of
disease treatments, such as percutaneous coronary intervention and coronary
artery bypass grafting surgery, for which the primary goals are to improve health
status as well as quality of life. Health-related quality of life is also a possible
source of variance that can often be observed between two patients with the
same degree of illness who experience different disease outcomes (Guyatt,
Feeny, & Patrick, 1993). Following are examples of studies highlighting quality of
life outcomes in cardiovascular patients.
Chronic heart failure is a disease that is increasing in prevalence and
promotes poor quality of life due to difficulty breathing, chronic fatigue, multiple
re-hospitalizations and peripheral edema which impair daily activities. An
additional source of importance for quality of life measures is the expressed
desire by the majority of a sample of chronic heart failure patients for an
improvement in quality of life over survival (Staneck, Oates, McGhan, Denofrio,
& Loh, 2000).
The general consensus of chronic heart failure patients is well stated by
Archana (2002):
It is not sufficient, therefore, to offer a patient improved survival and add
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years to life unless at the same time treatment also adds life to years…from a
patients’ perspective, the limitations imposed which adversely affect quality
of life and impact upon day-to-day activities at home, leisure time interests
and performance at work are of at least equal importance to the constellation
of symptoms and signs that form the basis of the medically oriented approach
to health assessment. (p. 1806-1807)
Chronic heart failure patients have been observed to experience impairments in
all domains of health related quality of life as measured by the SF-36. The
physical functioning aspect of quality of life in these patients also has been found
to be more severely impaired than in other common chronic illnesses (Hobbs et
al., 2002). Poor health-related quality of life has also been associated with
adverse outcomes and mortality in chronic heart failure patients (RodigeuzArtalejo et al., 2005) and has been predictive of clinical endpoints which indicate
that it is a valid measure of health status (Tate et al., 2007).
Peripheral artery disease is classified as a chronic illness for which one of
the main goals of treatment is to improve quality of life. Some studies suggest
that quality of life in peripheral artery disease patients may generally be poorer
than that of chronic heart failure patients (Liles, Kallen, Peterson, & Bush, 2006).
Peripheral artery disease limits daily activities and exerts adverse effects on
quality of life by impairing walking ability, hindering sleep, decreasing energy,
causing leg pain and sometimes requiring amputation or other surgical
interventions. Patients report severe limitations in mobility and feelings of
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inadequacy, fear, uncertainty and being a burden to family and friends which
severely impairs physical as well as mental health related quality of life (Nehler,
McDermott, Treat-Jacobson, Chetter, & Regensteiner, 2003). In recent years,
the importance of quality of life on the treatment on peripheral artery disease
patients has been highlighted, and the need to consider the broader impacts of
peripheral artery disease beyond clinical symptoms and mortality has been
emphasized. Subjective measures of quality of life have been correlated to
functional status and objective measures of disease severity. Low scores on the
mental health dimension of quality of life can also cause further impairment of
physical health status. Patients who are asymptomatic or experience mild
symptoms of disease may not function to the full extent of their capabilities due
to their subjective perceptions of their health status (Liles et al., 2006).
Within the population of myocardial infarction patients, main
contributors to impaired quality of life, compared to healthy community controls
four and five years post myocardial infarction, are reported to be the inability to
work, angina, emotional distress, difficulty sleeping and dyspnea (Brown et al.,
1999; Wiklund, Herlitz, & Hjalmarson, 1988). The degree of impairment in the
quality of life of myocardial infarction patients has also been associated with
reduced left ventricular ejection fraction and younger age (Petterson, Kvan,
Rollag, Stavem, & Reikvam, 2008; Bengtsson, Hagman, & Wedel, 2001). A
reduced quality of life has also been observed in female as opposed to male
myocardial infarction patients (Agewall, Berglund, & Henareh, 2003).
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Additionally, interviews of 2,320 male myocardial infarction patients suggest that
impairments in mental quality of life, more precisely high levels of stress, social
isolation, depression, anxiety, hostility and anger, may be associated with
mortality including sudden cardiac death (Ruberman, Weinblatt, Goldberg, &
Chaudhary, 1984; Peters, 2001). Percutaneous coronary intervention and
coronary artery bypass grafting surgery are two revascularization procedures
which aim to improve quality of life. Both of these procedures have been
demonstrated to equally improve health related quality of life scores six months
post-revascularization (Rumsfeld et al., 2003). Additionally, poor physical health
related quality of life has been demonstrated to be an independent predictor of
mortality following coronary artery bypass grafting surgery (Rumsfeld et al.,
1999).
Biochemical Markers
Additional indicators of prognosis in cardiovascular disease are proinflammatory cytokines which are substances released by immune cells in
response to tissue injury or infection. Cytokines provoke an immune response
drawing white blood cells to the damaged area in order to stimulate tissue
repair. Two members of the pro-inflammatory cytokine family are tumor
necrosis factor-alpha (TNF-α), and interleukin-6 (IL-6). These substances are
activated in a chemical cascade and necessary for immune activation. All
produce effects of hyperalgesia via release of prostaglandins, nerve growth
factor, sympathetic activation and direct activation of peripheral nocioceptors
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(Watkins & Maier, 2000). Pro-inflammatory cytokines often are up-regulated in
heart failure patients as they are released by myocardial cells, most notably TNFα and its soluble receptors (sTNFR-1 and sTNFR-2), in response to cardiac stress.
High levels of TNF-α, sTNFR-1, sTNFR-2, and IL-6 have consistently been linked to
severity of heart failure and cardiac mortality with sTNFR-2 levels being the most
accurate predictor of cardiac mortality (Murray & Freeman, 2003; Valgimigli et
al, 2005; Ueland et al, 2005; Deswal et al., 2001). Increased levels of proinflammatory cytokines are also associated with the pathogenesis of both
atherosclerosis and chronic heart disease (Yudkin, Kumari, Humphries, &
Mohamed-Ali, 2000).
Anti-inflammatory cytokines aid in regulation of the inflammatory
immune response via cytokine inhibitors and soluble cytokine receptors. Two
varieties of anti-inflammatory cytokines are interleukin-10 (IL-10) and
interleukin-1 receptor antagonist (IL-1ra). A very delicate balance of pro- and
anti-inflammatory cytokines is vital in order to ensure a fully functional and
healthy immune system. Disruptions to this balance are extremely detrimental
and often result in excessive inflammation and disease. The mechanism of action
of IL-1ra is to act as a competitive inhibitor at pro-inflammatory interleukin-1
receptor sites. IL-10 is considered the most essential anti-inflammatory cytokine
and works as an inhibitor of activity and production of a wide range of proinflammatory cytokines as well as an inhibitor of specific surface expression
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molecules which signal an inflammatory response (i.e MHC II complex
molecules) (Opal & DePalo, 2000).
Cortisol is a glucocorticoid often referred to as a stress hormone released
in response to sympathetic stimulation via the hypothalamic-pituitary-adrenal
axis. It has been demonstrated that the hypothalamic-pituitary-adrenal axis is
stimulated by increases in negative affect resulting in increased cortisol levels
(Buchanan, al’Absi, & Lovallo, 1999; Sher, 2005). Chronically elevated cortisol has
a disease promoting effect via its influence on the deposition of abdominal
adipose tissue which is a predictor of cardiovascular disease (Rimm et al., 1995)
via its hyperlipidemia and insulin resistant effects (Sher, 2005). In addition,
cortisol has an inhibitory effect on growth hormone causing growth hormone
deficiencies which are associated with a greater risk of premature cardiovascular
disease (Erfuth, Bulow, Asklisson, & Hagmar, 1999; Hew, O’Neal, Kamarudin,
Alford, & Best, 1998). An important aspect of human circadian rhythm is the
cortisol awakening response. The general secretory pattern of cortisol is a large
increase in secretion resulting in peak cortisol levels after awakening followed by
a decrease in cortisol levels throughout the day ending with the lowest levels at
night and in the early hours of the morning. This is a pattern of increased levels
of cortisol by 50-75% release within thirty minutes of awakening (Clow, Thorn,
Evans, & Hucklebridge, 2004) and has been suggested to be a reliable biological
marker of adrenocortical activity (Pruessner et al, 1997). Increased levels of the
cortisol awakening response have been observed in chronically stressed
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individuals in comparison to unstressed controls (Schulz, Kirschbaum, Prubner, &
Hellhammer, 1998) whereas increased net output of cortisol throughout the day
has been correlated with abdominal obesity (Rosmond, Dallman, & Bjorntorp,
1998).
Summary and Purpose of Current Study
In addition to the numerous investigations linking Type-D personality to
various known risk factors for cardiac morbidity and mortality, there is a
significant amount of research examining this personality type’s value as a
prognostic predictor following the diagnosis of heart disease using MACE, quality
of life, and biochemical marker endpoints. Though much work has been
conducted in examination of the topic as well as a handful of narrative reviews,
no meta-analysis has been conducted in this area. The completion of a metaanalysis demonstrates the size of the relationship of Type-D personality with
cardiac prognosis following the diagnosis of heart disease using the combined
quantitative data from multiple studies. The use of data from multiple studies
results in greater statistical power than in the individual studies and thus
provides a better overview of the state of the research. Therefore, the objective
of the current study is to conduct a meta-analytic review of the associations
between Type-D personality and 1) Major adverse cardiac events 2) Quality of
Life and 3) Levels of Biochemical Markers.
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Methods
Study Search Procedure
Two search procedures were utilized in order to obtain studies used in
the present meta-analysis. First, a keyword search was conducted on the
PsycINFO and PubMed databases. The searches were limited to publications in
the English language and primary studies. All publications up to the time of the
search were eligible. The keyword combinations were Type-D personality +
heart, Type-D personality + mortality, Type-D personality + cardiac mortality and
Type-D personality + left ventricular ejection fraction. All titles and abstracts
were examined and potential candidates for the meta-analysis were collected.
Second, an ancestral search was conducted using the Schiffer et al. (2009)
article as a starting point due to its status as the most recent publication at the
time the ancestral search was conducted. References of all articles obtained
during the keyword search were also analyzed for potential studies. Any titles
pertaining to the current topic of study were identified and their abstracts were
checked for inclusion into the pool of candidate studies for the meta-analysis.
Studies were added as they were located by both the principal investigator and
two Ph.D. level collaborators.
Inclusion and Exclusion Criteria
Candidate studies had to meet specific criteria for inclusion into the
meta-analysis. Studies must (a) have a sample patient population with a
diagnosis of chronic heart failure, coronary heart disease, myocardial infarction,
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acute coronary syndrome, peripheral artery disease or have undergone
percutaneous coronary intervention, implantable cardioverter defibrillator
implantation, coronary artery bypass grafting surgery, heart transplantation
surgery or be participating in a cardiac rehabilitation program; (b) compare
subsamples of patients diagnosed as Type-D vs. non Type-D; (c) Type-D must be
assessed using the DS-14, DS-16, DS-24 or a reliable and valid measure of both
negative affectivity and social inhibition separately in which high levels of both
negative affectivity and social inhibition are used to classify Type-D patients; (d)
the study endpoint must be either major adverse cardiac events (MACE), quality
of life measures or levels of disease promoting biochemical markers.
At the conclusion of the search, there were fifty potential studies relating
Type-D personality to heart disease. Of those studies, five were excluded
because they either lacked a non Type-D subsample for comparison or assessed
only negative affectivity or social inhibition individually. An additional three
studies were excluded because they used healthy patient samples. Of the
remaining 42 studies, 18 did not include the selected inclusion outcome
measures. An additional five studies were excluded due to the use of the same
patients in multiple studies, and one study was excluded due to a lack of cardiac
events in either patient group. A final four studies were unable to be used in
calculations of effect sizes because not enough statistical data were provided to
calculate an effect size (e.g standard deviations missing). The authors of these
studies were contacted in an attempt to gather additional data but no reply was
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received. This left 14 studies in the analysis which were then split into three
categories based on their endpoints: five studies were analyzed with an endpoint
of MACE, five studies were analyzed for quality of life and four were analyzed
with respect to biochemical markers (Figure 1).
Type-D Measurement in Primary Studies
The studies included in the analysis most often utilized the Type-D Scale14 (DS-14) and the Type-D Scale-16 (DS-16) for the assessment of Type-D
personality. On these diagnostic tools, patients indicate the extent to which they
agree with statements concerning negative affectivity and social inhibition levels
using five point Likert-type scales. A rating of 0 indicates disagreement with the
statement whereas a rating of 4 indicates agreement. There are eight items to
assess negative affectivity and eight items to assess social inhibition on the DS-16
(Denollet et al., 1996) whereas there are seven of each on the DS-14, the
successor of the DS-16 (Emons, Meijer, & Denollet, 2007). The DS-16 and DS-14
both demonstrate evidence of internal consistency as measures of Type-D
personality with α=.89 and .88 for measures of negative affectivity and α=.82
and .86 for social inhibition respectively (Denollet, 2005; Denollet et al., 1996).
The cutoff for a classification of Type-D personality is a score of 10 or greater on
both subscales. A median split using a cardiac population was used to establish
the cutoff point (Denollet, 2005). The Negative Affectivity subscale highly
correlates with the Trait Anxiety Scale (r=.81) whereas the Social Inhibition
subscale highly correlates with the Erdman Inhibition Scale (r=.73) (Denollet,
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1998). The DS-14 has been assessed using item response theory in both general
and clinical populations. Item response theory is a method used to assess the
measurement of variables that cannot be directly observed, referred to as latent
variables, as well as to assess the precision of cutoff scores used in diagnostic
tools. The item response theory assessment of the DS-14 supports the use of the
established cut off points in differentiating between Type-D and non Type-D
personality in both clinical and non clinical populations (Emons et al., 2007).
Quality of Life Measurement in Primary Studies
The SF-36 (Appendix A) is a 36 item self-evaluation of health status
containing scaled measurements for eight different aspects of health: physical
functioning, social functioning, role limitation due to physical functioning, role
limitations due to emotional functioning, mental health, vitality, pain and the
perception of general health (Kaplan, n.d). This evaluation is not disease-specific
and assesses a wide range of the dimensions contributing to overall health. The
scores for each individual dimension are coded and combined to produce an
overall score of health ranging from 0 (poor health) to 100 (excellent health).
Cronbach’s α exceeds the standard value of 0.85 in all dimensions except social
functioning (α=.73). The SF-36 also has adequate levels of test-retest reliability at
two weeks among each of the eight dimensions, with r-values ranging from .60
to .80, as well as shows strong evidence of construct validity as the SF-36 is able
to discriminate between patient groups with anticipated differences in their
health status (Brazier et al., 1992).
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The Minnesota Living with Heart Failure Questionairre (MLWHFQ) is a
disease-specific assessment of the impact of disease on the quality of life of
chronic heart failure patients (Appendix B). The evaluation consists of 21 items
rated on a 6-point Likert-type scale rating the impact of heart failure on social,
physical, mental and emotional aspects of life. It assesses, overall, the extent to
which heart failure limits individuals from living their optimal lifestyle. High
scores indicate poor health status. This measurement has high internal
consistency with a Cronbach’s α ranging from .92 to .95 among numerous
studies (Rector, 2005). The Cantril Ladder of Life (Appendix C) is an additional
quality of life measure in which subjects are presented with a vertical ladder on
which the numbers 1-10 are presented (Jaarsma, Lesman-Leegte, Cleuren, &
Lucas, 2005). They subjectively evaluate their lives from 1 (worst possible life) to
10 (best possible life) (Newman, 2005). This is a very general instrument that
can be used in all populations and is often used among heart failure patients.
The Cantril Ladder of life has a two year test-retest coefficient of .7 (Horley &
Lavery, 1991). The Cantril Ladder of Life and the MLWHFQ have an overall
correlation coefficient of .36 (Jaarsma et al., 2005).
The Health Complaints Scale (Appendix D) assesses 12 somatic and 12
cognitive common health complaints (Denollet, 1994). This instrument has been
found to exhibit high internal consistency with a Cronbach’s α of approximately
.89 as well as sufficient test-retest reliability at three months with a Pearson’s
correlation coefficient of approximately .69. The Health Complaints Scale has
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shown good construct validity as correlated with the disability and well-being
dimensions of the Heart Patients Psychological Questionnaire (Denollet, 1994).
The World Health Organization Quality of Life assessment instrument
(WHOQOL) (Appendix E) is a 100 item quality of life measure providing a
culturally sensitive subjective self report measurement of a broad range of
dimensions of quality of life with respect to their various levels of importance
(Trompenaars, Masthoff, Van Heck, Hodiamont, & De Vries, 2005; World Health
Organization, 1997). It has high levels of internal consistency with Cronbach’s α
ranging from .73 to .91 among the five sub-domains of physical health,
psychological health, level of independence, social relationships and
environment as well as α=.91 for overall quality of life and general health. The
WHOQOL has also been shown to exhibit an adequate level of construct validity
when correlated with multiple related questionnaires such as the Sickness
Impact Profile, Fatigue Impact Scale, Self-Esteem Scale, Life Orientation Test,
Social Support Questionnaire, Profile of Moods Scale and the Standard Bipolar
Five-Factor Markers (De Vries & Van Heckk, 1997).
Coding of Study Characteristics
Each study was coded independently for both study level characteristics
and effect size level characteristics (Lipsey & Wilson, 2001; Appendix F). The
clinical variables which were coded were those most consistently reported in the
primary studies. Common authors and sample sources were included in the
coding due to the concentrated group of investigators as well as limited
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geographical area in which Type-D research has been conducted. The recorded
study level characteristics were: publication year, inclusion of Denollet or
Pederson as authors, sample source (by hospital or cardiac rehabilitation
program), specific cardiac diagnosis/treatment/procedure, gender proportion
(percentage male), mean age, method of patient selection, study design, sample
size and diagnostic tool used to assess Type-D personality. Also recorded for
study level characteristics were the proportions of the sample engaging in
tobacco use, with impaired left ventricular ejection fraction (LVEF),
hyperlipidemia, hypertension, diabetes, renal impairment, NYHA Class III/IV and
with Type-D personality. It was also noted whether the baseline characteristics
significantly differed between the Type-D and non Type-D groups. The studylevel characteristics were examined as a source of possible extrinsic and
substantive variables in moderator analysis.
The recorded effect size level characteristics (Appendix F) were: length of
time of study, specific outcome construct measured, type of data effect size is
based on (dichotomous frequencies and proportions indicating the occurrence of
an event or means and standard deviations), page number on which the effect
size data was found, better or worse outcome for Type-D group, either all
dichotomous frequencies and proportions or means and standard deviation
data, whether Type-D personality was found to be a significant predictor of
worse outcome using 1) univariate significance testing and 2) multivariate
significance testing and the confidence rating in effect size computation based
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on whether any estimation was necessary for data presented graphically without
presentation of exact numbers. The confidence in the data was rated on a scale
of 1-5. A rating of 1 indicated a high level of estimation with minimal statistical
data. A rating of 2 indicated moderate estimation. For example, this would be
necessary for studies reporting only multifactor ANOVA statistics as a basis for
estimation. A confidence rating of 3 required some estimation such as that due
to unconventional statistics needing to be converted to conventional statistics or
incomplete conventional statistics. A rating of 4 required only slight estimation
whereas a confidence rating of 5 required no estimation and effect sizes could
be calculated directly from the data (Lipsey & Wilson, 2001). The effect size level
coding provided the data necessary to compute effect sizes and provided a
source of possible method variables in moderator analysis.
All coding was completed independently by two individual coders: the
primary investigator of this study and an individual with a master’s degree in
cardiac rehabilitation/exercise physiology. A coding book (Appendix F) and
coding sheets (Appendix G) were developed by the primary investigator and the
second coder was provided with extensive training with the well-defined coding
book (Appendix F). There was agreement on 100% of the study level
characteristics and 98.6% of the effect size level characteristics for studies
included in the MACE analysis. For the studies included in the quality of life
analysis there was 100% agreement on the study level characteristics and 99.4%
agreement on the effect size level characteristics. There was 100% agreement on
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both study level and effect size level characteristics for studies included in the
biochemical markers analysis. In cases of disagreement a decision was made
following the conference of the raters.
Effect Size Computation
Effect sizes were computed and presented as either odds ratios or
Hedge’s d. Effect sizes were reported as odds ratios when individual effect sizes
were gathered from dichotomous frequencies and proportions and were
reported in the terms of Hedge’s d when the individual effect size data was
derived from means and standard deviations. In analyses that combined effects
from multiple studies, effect sizes were weighted by their inverse variance. All
effect sizes were computed using Comprehensive Meta-Analysis Software
(Biostat, 2002).
For the MACE analysis, only one overall effect size was calculated. There
were two effect sizes calculated in the quality of life analysis: one using the
combined effects from studies with continuous data as well as one computed
from studies with dichotomous data. In the biochemical markers analysis
multiple effect sizes were calculated. First, effect sizes were calculated
individually for each of the inflammatory cytokines IL-6 and TNF-α, as well as
TNF-α soluble receptors sTNFR-1 and sTNFR-2. An effect size was then calculated
for TNF-α combined with sTNFR-1 and sTNFR-2. These were then combined
along with IL-6 to obtain an overall inflammatory cytokine effect size. An effect
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size was then computed for combined anti-inflammatory chemicals IL-10 and IL1ra. Lastly, the effect size for cortisol levels was computed.
Test of Homogeneity
A test of homogeneity is an indicator of the extent to which each
individual effect size is an estimate of the same population effect. This test is
represented by the variable Q. In a sample yielding a homogenous effect size, Q
is non-significant (p>.05) signifying that the individual effect sizes within the
overall mean effect size only differ with respect to sampling error. For samples in
which Q is significant (p<.05) the individual effect sizes are said to be
heterogeneous implying that individual effect size differences do not result from
only sampling error. In this case, other moderators must be considered in further
analysis as potential sources which could account for the heterogeneity of the
individual effect sizes (Hedges, 1982; Lipsey & Wilson 2001)
In samples in which the number of individual effect sizes is small, the
statistical power of Q is reduced resulting in the possibility that the test of
homogeneity may fail to indicate a heterogeneous sample when a
heterogeneous sample is present. For this reason, we have also included values
for the I2 index to complement the Q statistic results. The I2 statistic not only
indicates whether or not heterogeneity is present but also provides information
about the extent to which individual effect sizes are heterogeneous. By
convention, the values of I2=0 (0%), I2=25 (25%), I2=50 (50%), and I2=75 (75%)
indicate homogeneity, low heterogeneity, medium heterogeneity, and high
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heterogeneity respectively (Huedo-Medina, Sanchez-Meca, & Marin-Martinez,
2006). If heterogeneity was indicated based on a significant Q-value, each
individual study included in the effect size calculation was examined for potential
moderators. The identified potential moderators were then discussed as
variables to be considered for future research in this area
Meta-Analytic Model
Multiple meta-analytic models can be utilized in the completion of a
meta-analysis: fixed-effects, random-effects or mixed-effects. The fixed-effects
model is used when the source of heterogeneity between studies included in the
analysis is believed to have come from the study level and effect level coding
characteristics. A random-effects model is appropriate when variance between
studies is ascribed to sources of variability that are assumed to be randomly
distributed beyond random sampling error. Lastly, when the variance between
studies beyond that which can be attributed to sampling error is thought to be
primarily systematic but an additional random component of effect size
distribution is still present, a mixed-effects model should be employed (Lipsey &
Wilson, 2001). Due to the presence of heterogeneity in the present analysis that
was not systematic, the random-effects model was utilized.
Results
A summary of all numerical values for individual statistics is provided in
Table 2.
Major Adverse Cardiac Events Analysis

24

There were five studies included in the analysis with MACE as endpoints.
This yielded five individual effect sizes from a total of 2,066 cardiac patients
(Type-D=584, non Type-D= 1,482). All studies utilized a longitudinal design,
included either Denollet or Pederson as researchers and had a patient sample
that was more than 50% male in composition. Three studies took place in
Belgium with patients from the Antewerp Cardiac Rehabilitation Program
whereas the remaining two studies were conducted in the Netherlands. Four of
the five studies reported 20-29% prevalence of Type-D personality whereas one
study reported Type-D prevalence between 30-39%. One study reported the
Type-D sample as being more likely to smoke than the non Type-D sample
whereas no other significant differences in baseline characteristics between the
two groups were reported. All studies were rated at 100% confidence as all
necessary data for effect size calculation was provided, and no estimation was
needed.
The test of homogeneity produced a non-significant Q=3.27 indicating
homogenous individual effect sizes. This was further verified by an I2 value of 0%.
Type-D personality was associated with a higher occurrence of MACE (OR=3.42,
95% CI=2.48-4.73, p<.001). These results demonstrate that individuals with TypeD personality have more than three times greater odds of suffering a myocardial
infarction, percutaneous coronary intervention, coronary artery bypass grafting
surgery or cardiac death following the diagnosis of heart disease than those
without Type-D personality.
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Quality of Life Analysis
A total of five studies were included in the quality of life analysis. Two of
these studies were included in the computation of a single effect size as data
were presented dichotomously with a total sample size of 521 patients (TypeD=188, non Type-D=333). The remaining three studies were included in an
additional computation of effect size as continuous data were provided with a
total sample size of 368 patients (Type-D=98, non Type-D=270). Three studies
were completed in the Netherlands, two in Sweden and one in the UK. Three of
the five studies included either Denollet or Pederson as researchers. Two studies
were longitudinal whereas the remaining three were cross sectional. One study
reported that, at baseline, Type-D patients were more likely to have diabetes
and have a lower level of education than non-Type-D patients. No other
differences in baseline characteristics were reported. In all studies, greater than
50% of the sample was male and mean ages were within the range of 50-69
years. Two studies reported the prevalence of Type-D personality to be 20-29%,
two reported the prevalence to be 30-39%, whereas one study had an
abnormally high prevalence of Type-D personality within the range of 40-49%.
The data from four of the studies was rated at 100% confidence. One study
required slight estimation of means and standard deviations from a figure
presented graphically and, therefore, confidence was rated as 3.5 out of 5.
Analysis of the quality of life studies presenting data dichotomously
produced a significant effect size (OR=3.48, CI= 2.37-5.11, p<.001) as well as
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homogeneity between studies (Q=.21, p=.65, I2=0) indicating that individuals
with Type-D personality have more than three times greater odds of
experiencing a poor quality of life when diagnosed with heart disease than nonType-D individuals. In the analyses which included the three studies with
continuous data, the test of homogeneity resulted in a significant Q value of
51.88 (p<.001) and an I2 value of 96.15% indicating the presence of
heterogeneity beyond sampling error alone. The effect size for the relationship
between the presence of Type-D personality and poor quality of life was found
to be significant (d=-1.23, p=.01).
Potential sources of moderators between individual studies as sources of
heterogeneity in the data were identified. Aquarius (2007) had an increased
proportion of smokers and small sample size. Karlsson (2007) differed with
respect to investigators and a very general and simplistic measure of quality of
life versus the detailed MLWHFQ and WHOQOL-BREF utilized in the other
studies. Specific cardiac diagnosis and quality of life measurement differed
among all three studies.
Before these results are discussed further, a narrative review of the
results of the four excluded quality of life studies is warranted. The first of the
four excluded studies was conducted at Tweesteden Teaching Hospital in Tilburg,
Netherlands on 166 patients being treated for chronic heart failure. The patients’
disease-specific quality of life was assessed using the MLWHFQ and general
health status was assessed with the SF-36 at baseline and a one year follow-up.
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Though there was an overall improvement in general health status over time,
Type-D’s reported poorer disease-specific as well as general physical and mental
health status at both time points. Type-D was an independent predictor of poor
disease-specific mental health status, social functioning, role emotional
functioning, general health and increased bodily pain following multivariate
analysis (Schiffer et al., 2008). The second excluded study, also in Tilburg,
Netherlands at St. Elisabeth Hospital, examined the relationship of Type-D
personality with quality of life and stress in 150 peripheral artery disease
patients. Quality of life was measured with the WHOQOL-100 and the Perceived
Stress Scale-10. Type-D personality was equally present in patients with mild,
moderate and severe levels of disease though Type-D patients reported poorer
quality of life and more perceived stress than non Type-D patients. After
adjustments for disease status, age and gender, Type-D personality remained
significantly associated with an impaired quality of life (Aquarius, Denollet,
Hamming, & De Vries, 2005). The third excluded study was conducted with 186
surviving heart transplant recipients transplanted at the Erasmus Medical Center
in Rotterdam, Netherlands between 1985 and early 2003. Perceived health
related quality of life was assessed with the SF-36. Type-D transplant recipients
reported poorer quality of life than non Type-D patients on all aspects of the SF36, excluding bodily pain. Type-D personality was an independent predictor of
poor outcome on all dimensions of the SF-36 except bodily pain and general
health. Of interest, the 18% prevalence of Type-D personality in this study was
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abnormally low in comparison to other samples. It is hypothesized that this could
be due to the greater mortality rates of Type-D patients as evidenced in other
studies as well as this meta-analysis, or the socially inhibited manner in which
Type-D patients tend to present themselves resulting in a possible decreased
patient advocacy and reduced placement of Type-D patients on the heart
transplant list (Pederson et al., 2006). The final excluded study assessed the
relation between Type-D personality and health related quality of life at baseline
and three months in 154 implantable cardioverter defibrillator implantation
patients. Quality of life was measured by the SF-36. Though general
improvement was observed with time, Type-D patients consistently reported
poorer quality of life than non Type-D patients (Pederson, Thomas, MuskensHeemskerk, Erdman, & Jordaens, 2007).
Biochemical Markers Analysis
There were a total of four studies with endpoints of biochemical markers
of disease. All analysis conducted with pro-inflammatory cytokines was
conducted from the data of 305 patients (Type-D=105, non Type-D=200)
whereas anti-inflammatory cytokine analysis encompassed 84 patients (TypeD=32, non Type-D=52) and cortisol analysis included 66 patients (Type-D=23, non
Type-D=43). Two studies were conducted in Belgium, one in England and one in
the Netherlands. Three of the four studies included either Denollet or Pederson
as researchers. Three studies were cross-sectional in design whereas one was
longitudinal. Two studies found Type-D patients more likely to be NYHA Class
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III/IV at baseline, one study reported that Type-D patients were more likely to be
older, and one study reported Type-D patients as more likely to be taking
diuretics. No other significant differences at baseline were reported. All studies
consisted of samples with more than 50% males and a 30-39% prevalence of
Type-D personality. All studies were rated at 100% confidence as all data
necessary for calculating effect sizes was provided and no estimation was
needed.
The levels of inflammatory cytokine IL-6 were found to be elevated in
patients with Type-D personality (d=-.26, p=.03) and the test of homogeneity
indicated homogenous individual effect sizes (Q=.04, p=.98, I2=0%). The analysis
of elevated inflammatory cytokine TNF-α and its soluble receptor levels (d=-1.58,
p=.07) and combination analysis of elevated IL-6, TNF-α, sTNFR-1, and sTNFR-2
levels (d=-1.10, p=.07) in Type-D versus non Type-D individuals both trended
towards significance. Both TNF-α, sTNFR-1, and sTNFR-2 combined analysis
(Q=76.30, p<.001, I2=97.39%) and the combined IL-6, TNF-α, sTNFR-1, and
sTNFR-2 (Q=48.37, p<.001, I2=95.87%) analysis were also found to be
heterogeneous indicating that the variance among individual effect sizes cannot
be explained by mere sampling error. The effect size for TNF-α excluding the
effects of sTNFR-1 and sTNFR-2 was found to be insignificant (d=-1.07, p=.17) as
well as heterogeneous (Q=67.07, p<.001, I2=97.02%). Significance was found for
the effects of sTNFR-1 and sTNFR-2 alone (d=-1.82, p=.05), however,
heterogeneity was present (Q=81.97, p<.001, I2=97.56%). In analysis of anti-
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inflammatory chemicals IL-10 and IL-1ra (d=-.42, p=.06) the results also trended
towards significance with Type-D individuals having lower levels of antiinflammatory cytokines. The last biochemical analysis of the association between
Type-D and cortisol levels did not produce significant results (d=-.24, p=.35).
All heterogeneous studies were examined for the presence of potential
moderators. Denollet (2009) was identified as a possible source of variance due
to a greater proportion of the sample being classified as NYHA Class III/IV, a
greater mean sample age, the presence of kidney dysfunction in fourteen of the
Type-D patients and a longitudinal study design whereas the other studies were
cross-sectional.

Discussion
Results from the MACE analysis demonstrate a large effect size indicating
the association of Type-D personality with odds of experiencing a myocardial
infarction, cardiac mortality, coronary artery bypass grafting surgery and
percutaneous coronary intervention that are more than three times greater than
in non Type-D individuals. When quality of life data were presented
dichotomously, indicating only whether quality of life was impaired or not, the
results indicated that Type-D patients had more than three times greater odds of
being classified as having a poor quality of life than those without Type-D
personality. When data were presented continuously, indicating the severity
with which quality of life was impaired, in the form of numerical scores on the
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various quality of life assessments, the effect size was also found to be
significant. The consistent results of the four previously summarized excluded
studies which assess quality of life in heart disease patient groups using similar
and psychometrically accepted instruments also support the presence of a
relationship between Type-D personality and poor health-related quality of life.
The increased sample size would also have increased the statistical precision and
perhaps have provided a more homogenous outcome.
The test of homogeneity with respect to the continuous data quality of
life analysis implies the presence of moderators in the studies contributing to
heterogeneity beyond that solely from sampling error. One of these possible
moderators is the variety of quality of life measures used in the studies. Three
different quality of life measures were used in the analysis, and though they all
have a common objective of measuring quality of life, each differed with respect
to the others. The SF-36 and Cantril Ladder of Life both measure general quality
of life whereas the MLWHFQ is disease specific. The Cantril Ladder of Life is a
very general single measure of the discrepancy between the patients’ real versus
ideal life whereas the SF-36 and MLWHFQ results are based on a combination of
scores on multiple detailed dimensions of quality of life. Though all studies used
cardiovascular disease patient populations, each of three studies included
patients with differing diagnoses. The three patient populations were either
diagnosed with acute myocardial infarction or peripheral artery disease,
underwent coronary artery bypass grafting surgery, or were generally referred to
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cardiac rehabilitation with no specific diagnosis provided. This raises the
possibility that differing diagnoses, though all falling under the umbrella of
cardiovascular disease, may be associated with the variation between effect
sizes. Additionally, one study took place over a twelve week period with quality
of life measurements taken at both baseline and twelve weeks. However, the
patient sample underwent cardiac rehabilitation between quality of life
measures so only baseline data were utilized in the effect size calculation in
order to reduce variability between studies. One study was prospective in nature
but only provided quality of life scores using the Cantril Ladder of Life at baseline
whereas the other study was also prospective in nature but only provided raw,
unadjusted data usable in the present meta-analysis for baseline WHOQOL
scores. If all of these studies had had usable test-retest data, it is possible that
the quality of life scores may have presented a more precise picture of the
patients’ quality of life as well as less heterogeneity between the effect sizes.
These are important variables consider for future research in this area as well as
any future meta-analysis conducted when a larger sample size is available.
Of the biochemical markers, the inflammatory cytokines IL-6, sTNFR-1
and sTNFR-2 were most prominently associated with Type-D personality. Type-D
patients displayed significantly higher levels of these cytokines compared to non
Type-D patients. Though the elevated levels of TNF-α in Type-D patients did not
reach significance, when the TNF-α and its soluble receptor levels were
combined the results trended towards significance. This pattern may be due to
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the fact that the majority of TNF-α is found on cell surfaces and has a stimulatory
effect triggering the release of sTNFR-1 and sTNFR-2 into plasma. Therefore,
sTNFR-1 and sTNFR-2 are strong indicators of sustained elevated levels of TNF-α
and are regarded as more accurate predictors of adverse outcome in heart
disease, primarily chronic heart failure (von Haehling, Jankowska, & Anker,
2004). Additionally, it has been indicated that the plasma complex formed by
circulating TNF-α and its soluble receptors stabilizes TNF-α and enhances as well
as prolongs its pro-inflammatory effects in the body (Aderka, Engelmann, Maor,
Brakebush, & Wallach, 1992). The combined effect of elevated TNF-α, sTNFR-1,
sTNFR-2, and IL-6 levels in Type-D versus non Type-D patients also trended
towards significance. There was, however, a relatively small sample size for each
analysis resulting in the possibility that an increased sample size may have
caused the effect sizes that strongly trended towards significance to become
significant.
The individual effect sizes from which the overall effect size was
determined for these non significant analyses as well as the sTNFR-1 and sTNFR2 analysis were found to be heterogeneous indicating the presence of possible
moderators causing variance to be greater than that which can be explained by
sampling error alone. The studies varied slightly with respect to mean patient
ages of 57, 59.1 and 65.7 years. The study in which the mean patient age was
highest also had the highest levels of pro-inflammatory cytokines. TNF-α levels
have been positively correlated with advancing age (Deswal et al., 2001). The
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same study also included 14 Type-D patients with kidney dysfunction which is
also associated with increased pro-inflammatory cytokine levels (Knight et al.,
2004; Pecoits-Filho et al., 2003). This may explain a portion of the between study
variability and in future research clinical variables that have independent
associations with biochemical marker levels should be considered. It should also
be noted that all data used in the present meta-analysis were raw data
unadjusted for clinical variables such as age, gender, and disease severity.
Anti-inflammatory cytokine analysis presented a trend towards
significantly lower levels in Type-D versus non Type-D patients. Cortisol levels did
not differ between Type-D and non Type-D individuals. This may have been
affected by the measurement of awakening cortisol levels as well as cortisol
awakening response in a hospital setting where sleep patterns are interrupted by
ambient light and noises throughout the night. A study by Molloy and colleagues
(2008) measured cortisol awakening response as well as cortisol levels
throughout the day in a non-hospital setting using a patient sample overlapping
with that of our analysis. They also found no statistically significant difference
between Type-D and non Type-D patients with respect to the cortisol awakening
response. They did, however, find elevated levels of cortisol output throughout
the day in Type-D versus non Type-D individuals. A study using monozygotic and
dizygotic twin pairs found that chronic stress as well as genetics have a
substantial influence on cortisol levels after awakening but do not influence the
cortisol profile over the course of the day (Wust, Wolf, Federenko, Hellhammer,
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& Kirschbaum,2000). This is an area that may warrant further study, as there has
been much focus on the magnitude of the cortisol awakening response in
connection to disease.
Cardiac rehabilitation, particularly rehabilitation with a focus on relieving
emotional distress through group and individual interventions, has been shown
to reduce mortality in coronary heart disease patients (Denollet & Brutsaert,
2001). It also may decrease the level of impairment associated with Type-D
personality and may facilitate improvement in DS-14 scores to a more favorable
level (Binder, Kohls, Schmid, & Saner, 2007). In contrast, other studies have
observed improvements in the quality of life of Type-D patients following cardiac
rehabilitation without improvements in DS-14 scores (Karlsson et al., 2007).
There are a broad range of options available to alleviate the distress caused by
Type-D personality such as pharmacological intervention with anti-depressants
to increase social confidence and reduce the intensity of negative emotions,
psychotherapy to teach social skills and provide emotional support, cognitive
behavioral therapy or exercise (Sher, 2005). However, further research is
needed to determine whether any of these options to alleviate chronic stress as
well as emotional distress have any effect in Type-D individuals.
There are limitations to the present meta-analysis that should be noted.
These studies were conducted by a moderately concentrated group of
investigators and were restricted demographically to encompass patients from a
small number of countries in Europe. There is a need for additional research that
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encompasses a broader demographic to replicate the previous findings
concerning Type-D personality and adverse cardiac prognosis. Effect sizes,
particularly those concerning quality of life and biochemical markers, were
computed from small sample sizes, many of which were heterogeneous, which
enforces the need for a broader body of research on the topic. The abundance of
trends towards significance despite small effect sizes still strongly suggests an
association between Type-D personality and poor cardiac prognosis.
These findings converge to strongly suggest that Type-D personality is a
predictor of poor prognosis following a diagnosis of cardiovascular disease which
may possibly be explained by disease pathways involving pro- and antiinflammatory cytokines. This supports the need for a brief and simple screening
of cardiovascular patients for Type-D personality in order to provide
supplemental treatment to this high risk patient population.
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Appendix A
SF-36(tm) Health Survey
Instructions for completing the questionnaire: Please answer every
question. Some questions may look like others, but each one is different.
Please take the time to read and answer each question carefully by filling
in the bubble that best represents your response.
Patient Name: __________________
SSN#: ________________________________________ Date:_______
Person helping to complete this form:
___________________________________________________________
_____
1. In general, would you say your health is:
 Excellent
 Very good
 Good
 Fair
 Poor
2. Compared to one year ago, how would you rate your health in general
now?
 Much better now than a year ago
 Somewhat better now than a year ago
 About the same as one year ago
 Somewhat worse now than one year ago
 Much worse now than one year ago
3. The following items are about activities you might do during a typical
day. Does your health now limit you in these activities? If so, how much?
a. Vigorous activities, such as running, lifting heavy objects, participating
in strenuous sports.
 Yes, limited a lot.
 Yes, limited a little.
 No, not limited at all.
b. Moderate activities, such as moving a table, pushing a vacuum cleaner,
bowling, or playing golf?
 Yes, limited a lot.
 Yes, limited a little.
 No, not limited at all.
c. Lifting or carrying groceries.
 Yes, limited a lot.
 Yes, limited a little.
 No, not limited at all.
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d. Climbing several flights of stairs.
 Yes, limited a lot.
 Yes, limited a little.
 No, not limited at all.
e. Climbing one flight of stairs.
 Yes, limited a lot.
 Yes, limited a little.
 No, not limited at all.
f. Bending, kneeling or stooping.
 Yes, limited a lot.
 Yes, limited a little.
 No, not limited at all.
g. Walking more than one mile.
 Yes, limited a lot.
 Yes, limited a little.
 No, not limited at all.
h. Walking several blocks.
 Yes, limited a lot.
 Yes, limited a little.
 No, not limited at all.
i. Walking one block.
 Yes, limited a lot.
 Yes, limited a little.
 No, not limited at all.
j. Bathing or dressing yourself.
 Yes, limited a lot.
 Yes, limited a little.
 No, not limited at all.
4. During the past 4 weeks, have you had any of the following problems
with your work or other regular daily activities as a result of your physical
health?
a. Cut down the amount of time you spent on work or other activities?
 Yes  No
b. Accomplished less than you would like?
 Yes  No
c. Were limited in the kind of work or other activities
 Yes  No
d. Had difficulty performing the work or other activities (for example, it took
extra time)
 Yes  No
5. During the past 4 weeks, have you had any of the following problems
with your work or other regular daily activities as a result of any emotional
problems (such as feeling depressed or anxious)?
a. Cut down the amount of time you spent on work or other activities?
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 Yes  No
b. Accomplished less than you would like
 Yes  No
c. Didn't do work or other activities as carefully as usual
 Yes  No
6. During the past 4 weeks, to what extent has your physical health or
emotional problems interfered with your normal social activities with
family, friends, neighbors, or groups?
 Not at all
 Slightly
 Moderately
 Quite a bit
 Extremely
7. How much bodily pain have you had during the past 4 weeks?
 Not at all
 Slightly
 Moderately
 Quite a bit
 Extremely
8. During the past 4 weeks, how much did pain interfere with your normal
work (including both work outside the home and
housework)?
 Not at all
 Slightly
 Moderately
 Quite a bit
 Extremely
9. These questions are about how you feel and how things have been with
you during the past 4 weeks. For each question, please give the one
answer that comes closest to the way you have been feeling. How much
of the time during the past 4 weeks.
a. did you feel full of pep?
 All of the time
 Most of the time
 A good bit of the time
 Some of the time
 A little of the time
 None of the time
b. have you been a very nervous person?
 All of the time
 Most of the time
 A good bit of the time
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 Some of the time
 A little of the time
 None of the time
c. have you felt so down in the dumps nothing could cheer you up?
 All of the time
 Most of the time
 A good bit of the time
 Some of the time
 A little of the time
 None of the time
d. have you felt calm and peaceful?
 All of the time
 Most of the time
 A good bit of the time
 Some of the time
 A little of the time
 None of the time
e. did you have a lot of energy?
 All of the time
 Most of the time
 A good bit of the time
 Some of the time
 A little of the time
 None of the time
f. have you felt downhearted and blue?
 All of the time
 Most of the time
 A good bit of the time
 Some of the time
 A little of the time
 None of the time
g. did you feel worn out?
 All of the time
 Most of the time
 A good bit of the time
 Some of the time
 A little of the time
 None of the time
h. have you been a happy person?
 All of the time
 Most of the time
 A good bit of the time
 Some of the time
 A little of the time
 None of the time
i. did you feel tired?
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All of the time
Most of the time
A good bit of the time
Some of the time
A little of the time
None of the time

10. During the past 4 weeks, how much of the time has your physical
health or emotional problems interfered with your social activities (like
visiting friends, relatives, etc.)?
 All of the time
 Most of the time
 Some of the time
 A little of the time
 None of the time
11. How TRUE or FALSE is each of the following statements for you?
a. I seem to get sick a little easier than other people
 Definitely true
 Mostly true
 Don't know
 Mostly false
 Definitely false
b. I am as healthy as anybody I know
 Definitely true
 Mostly true
 Don't know
 Mostly false
 Definitely false
c. I expect my health to get worse
 Definitely true
 Mostly true
 Don't know
 Mostly false
 Definitely false
d. My health is excellent
 Definitely true
 Mostly true
 Don't know
 Mostly false
 Definitely false
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MINNESOTA LIVING WITH HEART FAILURE QUESTIONNAIRE
The following questions ask how much your heart failure (heart condition)
affected your life during the past month (4 weeks). After each question,
circle the 0, 1, 2, 3, 4 or 5 to show how much your life was affected. If a
question does not apply to you, circle the 0 after that question.
Did your heart failure prevent you
from living as you wanted during
the past month (4 weeks) by 1. causing swelling in your ankles or legs?
2. making you sit or lie down to rest during
the day?
3. making your walking about or climbing
stairs difficult?
4. making your working around the house
or yard difficult?
5. making your going places away from
home difficult?
6. making your sleeping well at night
difficult?
7. making your relating to or doing things
with your friends or family difficult?
8. making your working to earn a living
difficult?
9. making your recreational pastimes, sports
or hobbies difficult?

Very
No
Little
0

1

2

3

4

5

0

1

2

3

4

5

0

1

2

3

4

5

0

1

2

3

4

5

0

1

2

3

4

5

0

1

2

3

4

5

0

1

2

3

4

5

0

1

2

3

4

5

0

1

2

3

4

5

10. making your sexual activities difficult?
11. making you eat less of the foods you
like?

0

1

2

3

4

5

0

1

2

3

4

5

12. making you short of breath?
13. making you tired, fatigued, or low on
energy?

0

1

2

3

4

5

0

1

2

3

4

5

14. making you stay in a hospital?

0

1

2

3

4

5

15. costing you money for medical care?

0

1

2

3

4

5

16. giving you side effects from treatments?

0

1

2

3

4

5

11/10/04
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17. making you feel you are a burden to your
family or friends?
18. making you feel a loss of self-control
in your life?
19. making you worry?
20. making it difficult for you to concentrate
or remember things?

0

1

2

3

4

5

0

1

2

3

4

5

0

1

2

3

4

5

0

1

2

3

4

5

21. making you feel depressed?
0
1
2
3
4 5
__________________________________________________________________
_______
©1986 Regents of the University of Minnesota, All rights reserved. Do not copy or reproduce
without permission. LIVING WITH HEART FAILURE® is a registered trademark of the Regents
of the University of Minnesota.
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Appendix C

Cantril Ladder of Life
All of us want certain things out of life. When you think about what really matters in your
own life, what are your wishes and hopes for the future? In other words, if you image
you own future in the best possible light, what would you life look like then, if you are to
be happy? Take your time thinking about
this.
Now taking the other side to the picture, what are your fears and worries about the
future? In other words, if you image your future in the worst possible light, what would
your life look like then? Here is a picture of a ladder. The top of the ladder represents
the best possible life and the bottom the worst for you. Where on the ladder do you feel
you personally stand at the present time?
10 BEST POSSIBLE LIFE
9_________________
8_________________
7_________________
6_________________
5_________________
4__________________
3_________________
2_________________
1_________________
0 WORST POSSIBLE LIFE
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Appendix D
Health Complaints Scale
Name:_________________________ Sex:________ Age:_____
Date:__________
Below are a number of problems and complaints that ill people often have.
Please read each item carefully and then circle the appropriate number next to
that problem. Indicate how much each problem has bothered you lately. Please
use the following scale to record your answers.

0 NOT AL ALL 1 A LITTLE BIT 2 MODERATELY 3 QUITE A BIT 4
EXTREMELY

Lately, how much were you bothered by the following specific problems:
A1

Sleep that is restless or disturbed
0 1 2 3 4
A2

Tightness of the chest
0 1 2 3 4
A3

Feeling that you are not rested
0 1 2 3 4
A4

Fatigue
0 1 2 3 4
A5

Trouble falling asleep
0 1 2 3 4
A6

Inability to take a deep breath
0 1 2 3 4
A7

Stabbing pain in heart or chest
0 1 2 3 4
A8

Feeling exhausted without any reason
0 1 2 3 4
A9

Shortness of breath
0 1 2 3 4
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A10

Pain in heart or chest
0 1 2 3 4
A11

Feeling weak
0 1 2 3 4
A12

Feeling you can’t sleep
0 1 2 3 4
Lately, how much have you been bothered by the following problems:
B1

The idea that your bad health is the biggest problem in your life
0 1 2 3 4
B2

Not being able to work fluently, also with hobbies
0 1 2 3 4
B3

Being afraid of illness
0 1 2 3 4
B4

The idea that you were able to take on much more work formerly
0 1 2 3 4

B5

Feeling blocked in getting things done
0 1 2 3 4
B6

The idea that you have a serious illness
0 1 2 3 4
B7

Feeling you are not able to do much
0 1 2 3 4
B8

The idea that something serious is wrong with your body
0 1 2 3 4
B9

Feeling you are no longer worth as much as you used to be
0 1 2 3 4
B10

Feeling despondent
0 1 2 3 4
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B11

worrying about your health
0 1 2 3 4

B12

Thinking that all your worries would be over in you were physically healthy
0 1 2 3 4
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Appendix F
STUDY-LEVEL CODING MANUAL
Source Descriptors:
1. Study ID Number (In bold at beginning of reference)
2. Publication Year (Last two digits)
3. Does the study include either Denollet, J or Pederson SS in its list of
authors?
1. Yes
2. No
Sample Descriptors:
4. What is the source of the sample? Specify by the hospital or program from
which they were selected.
1. Antewerp Cardiac Rehabilitation Program/University Hospital of
Antewerp
2. Rotterdam Cardiology Hospital/Organization for Cardiac Rehabilitation
3. Harefield Hospital
4. TweeSteden Teaching Hospital
5. St. Elisabeth Hospital
6. London Hospitals
7. Danderyd Hospital
8. Erasmus Medical Center
9. General Practice
5. What is the specific cardiac diagnosis or necessary treatment/procedure of
the patients which qualified them for the study? Select multiple diagnoses if
the sample included more than one cardiac pathology or procedure.
1. Myocardial Infarction
2. Coronary Artery Bypass Grafting Surgery (CABG)
3. Angioplasty /Percutaneous Coronary Intervention (PCI)
4. Referred to/Participating in Cardiac Rehabilitation Program
5. Chronic/Congestive Heart Failure (CHF), specify if systolic/diastolic
noted
6. Peripheral Artery Disease (PAD)
7. Coronary Heart Disease (CHD)
8. Acute Coronary Syndrome (ACS)
9. Heart Transplant
10. Implantable Cardioverter Defibrillator (ICD) Implantation
6. Predominant gender of sample. Select the code for the correct proportion
of men in the sample.
1. <5% male
2. 5-50% male
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3. 50% male
5. >95% male

4. 50-95% male
6. Information not reported

7. Mean age of sample. Select correct age bracket or indicate that it is
stratified by percent greater than a specific age.
1. 20-49 years old
2. 50-59 years old
3. 60-69 years old
4. 70-79 years old
5. 80 years or older
6. Information reported as % of
7. Information not reported
sample greater than a specified age
(please specify the age)

8. Proportion of sample that engages in tobacco use. Select the correct
percentage bracket.
1. 0-24% smokers
2. 25-49% smokers
3. 50-74% smokers
4. 75-89% smokers
5. 90-100% smokers
6. Information not reported
9. Proportion of sample with impaired Left Ventricular Ejection Fraction
(LVEF). This has no absolute definition and is defined slightly different from
study to study. Select based on the proportion that is less than the cut-off
percentage specified in the study. For example, one study may specify the
proportion of patients with an LVEF <50% while another specified the
proportion with an LVEF <40%, code for the proportion defined as
impaired according to the specific study. Only a mean LVEF is provided
specify and provide the mean.
1. 0-24% impaired LVEF
2. 25-49% impaired LVEF
3. 50-74% impaired LVEF
4. 75-89% impaired LVEF
5. 90-100% impaired LVEF
6. Information not reported
7. Only mean LVEF reported (specify)
10. Proportion of sample with
hyperlipidemia/hypercholesterolemia/dyslipidemia. Select the correct
percentage bracket.
1. 0-24% high cholesterol
2. 25-49% high cholesterol
3. 50-74% high cholesterol
4. 75-89% high cholesterol
5. 90-100% high cholesterol
6. Information not reported
11. Proportion of sample with hypertension. Select the correct percentage
bracket.
1. 0-24% hypertension
2. 25-49% hypertension
3. 50-74% hypertension
4. 75-89% hypertension
5. 90-100% hypertension
6. Information not reported
12. Proportion of sample with diabetes. Select the correct percentage
bracket.
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1. 0-24% diabetes
3. 50-74% diabetes
5. 90-100% diabetes

2. 25-49% diabetes
4. 75-89% diabetes
6. Information not reported

13. Proportion of sample with renal impairment. Select the correct
percentage bracket.
1. 0-24% renal impairment
2. 25-49% renal impairment
3. 50-74% renal impairment
4. 75-89% renal impairment
5. 90-100% renal impairment
6. Information not reported
14. Proportion of sample classified as NYHA Class III and IV. Select the
correct percentage bracket.
1. 0-24% severe disease
2. 25-49% severe disease
3. 50-74% severe disease
4. 75-89% severe disease
5. 90-100% severe disease
6. No information reported
15. Proportion of the sample classified as Type-D Personality. Select the
correct percentage bracket.
1. 0-9% Type-D
2. 10-19% Type-D
3. 20-29% Type-D
4. 30-39% Type-D
5. 40-49% Type-D
6. 50-59% Type-D
7. 60-69% Type-D
8. 70-79% Type-D
9. 80-89% Type-D
10. 90-100% Type-D
11. Information not provided
16. Are the baseline characteristics of the Type-D’s vs. non Type-D’s
significantly different?
1. Yes (specify which aspects are significantly different)
2. No
3. Information not provided
Research Design Descriptors:
17. How were the patients selected? Choose best possible selection.
1. A consecutive series of patients at a particular hospital or rehabilitation
program were approached and asked to participate in the study
2. Patients being treated at a particular hospital or rehabilitation program
were approached and asked to participate in the study, however
whether they were consecutively selected is not indicated
3. Patients were selected from the registry of another larger study/database
4. Patients were selected based on past treatment received (retrospective
selection)
18. What was the study design? Choose the best possible selection.
1. Longitudinal
1a. Prospective
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1b. Retrospective
2. Cross Sectional
19. What was the total sample size of the study? Select the correct bracket.
1. <100 patients
2. 100-199 patients
3. 200-299 patients
4. 300-399 patients
5. 400-499 patients
6. >500 patients
20. What was the measure used to assess Type-D personality?
1. DS-14
2. DS-16
3. DS-24
4. Measure NA and SI separately and then
Combined to classify as Type D (please
specify which measures were used for NA
and SI)

EFFECT SIZE LEVEL CODING MANUAL
1. Study ID Number
2. Effect Size Number
Dependent Measure Descriptors:
3. Effect size type. Not sure how this applies because there isn’t really any
interventions, they all seem to be post-tests but some have multiple post tests
and some have only one so do we need to code for this and if so what options
would we use?
4. What was the length of time of the study. For studies in which follow up
varies, code for the mean time of follow-up.
1. 0 weeks
2. 1-4 weeks
3. 5-12 weeks
4. 13-24 weeks
5. 25-52 weeks
6. 53-156 weeks
7. 157-260 weeks
8. >260 weeks
5. What was the outcome construct that was measured? Select all subcategories that apply.
1. Major Adverse Cardiac Event
1a. Cardiac Death
1b. Myocardial Infarction
1c. PCI
1d. CABG
2. Quality of Life Measurement
2a. Health Complaints Scale
2b. Global Mood Scale
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2c. Short Form Health Survey SF-36
2d. Minnesota Living with Heart Failure Questionnaire
(MLWHFQ)
2e. World Health Organization Quality of Life Assessment
Instrument-100 (WHOQOL)
2f. Perceived Stress Scale-10
2g. Cantril Ladder of Life
3. Body Chemical Levels
3a. TNF-alpha
3c. IL-6
3e. IL-1ra

3b. sTNFR-1 and 2
3d. IL-10
3f. Cortisol

6. What was the type of data the effect size was based on?
1. Dichotomous frequencies and proportions
2. Means and standard deviations
3. Other (specify)
7. Specify the page number on which the effect size data was found
8. Was the outcome better or worse for the Type-D group? This should be
only based on the numbers and not on the significance reported in the study
1. Better
2. Worse
3. No Difference
9. When dichotomous frequencies and proportions are reported:
9a. What is the Type-D sample size?
9b. What is the non Type-D sample size?
9c. How many total events, or what proportion of the group experienced
an event occurred in the Type-D group? (when death is reported
the event should only be counted if it is a cardiac death)
9d. How many total events, or what proportion the group experienced an
event in the non Type-D group? (when death is reported the event
should only be counted if it is a cardiac death)
10. When means and standard deviations are reported:
10a. What is the Type-D sample size?
10b. What is the non Type-D sample size?
10c. What was the mean for the Type-D group?
10d. What was the mean for the non Type-D group?
10e. What was the standard deviation for the Type-D group?
10f. What was the standard deviation for the non Type-D group?
11. If a test of significance was completed, was having Type-D personality
found to be a significant predictor of a worse outcome? (If there is a case
where there was significance for some measurements but not others select
“1” and verify which outcomes were significant)
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1. Yes

2. No

3. Significance testing not
done

12. In studies when significance testing was done a second time using
multivariate logistic regression controlling for other variables/stepwise/logistic regression/MANCOVA, was having Type-D personality found to
be a significant predictor of a worse outcome? (If there is a case where there
was significance for some measurements but not others select “1” and verify
which outcomes were significant)
1. Yes
2. No
3. Multivariate testing not
done
13. Report the effect size to two significant figures using a plus sign when
there is a better outcome for the Type-D’s and a minus sign when there is a
worse outcome for the Type-D’s.
14. What is the confidence rating in effect size computation?
1. Highly estimated (have N and crude p-value only, such as p<.1, and
must reconstruct via rough t-test equivalence)
2. Moderate estimation (have complex but relatively complete statistics,
such as multi factor ANOVA, as a basis for estimation)
3. Some estimation (have unconventional statistics and must convert to
equivalent t-values or have conventional statistics but incomplete,
such as exact p-level)
4. Slight estimation (must use significance testing statistics rather than
descriptive statistics, but have complete statistics of conventional
sort)
5. No estimation (have descriptive data such as means, standard
deviations, frequencies, proportions, etc. and can calculate the
effect size directly)

67
Appendix G.
Study-Level Coding Form for Type-D Meta-Analysis
Bibliographic Reference:
Source Descriptors
1. Study ID Number:
2. Publication Year:
3. Denollet, J or Pederson SS an author?
Sample Descriptors
4. Source of the sample:
5. Specific cardiac diagnosis or treatment:
6. Predominant Gender:
7. Mean age:
8. Proportion engaging in tobacco use:
9. Proportion with impaired LVEF:
10. Proportion with hyperlipidemia/hypercholesterolemia/dyslipidemia:
11. Proportion with hypertension:
12. Proportion with diabetes:
13. Proportion with renal impairment:
14. Proportion NYHA Class III or IV:
15. Proportion with Type-D personality:
16. Baseline characteristics for Type-D’s and non Type-D’s significantly
different?
Research Design Descriptors:
17. How patients were selected:
18. Study design:
19. Total sample size:
20. Measure used to assess Type-D Personality:

Effect Size Level Coding Form for Type-D Meta-Analysis
1. Study ID number:
2. Effect size number:
Dependent Measure Descriptors
3. Effect size type:
4. Length of time of study:
5. Outcome construct measured:
6. Type of data the effect size was based on:
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7. Page number on which effect size data was found:
8. Outcome better or worse for Type-D group:
9a. Type-D sample size:
9b. Non Type-D sample size:
9c. n(total events in Type-D group):
9d. n(total events in non Type-D group):
10a. Type-D sample size:
10b: Non Type-D sample size:
10c. Type-D group mean:
10d. Non Type-D group mean:
10e. Type-D group standard deviation:
10f. Non Type-D group standard deviation:
11. With significance testing was Type-D a significant predictor of worse
outcome?
12. In controlled significance testing was Type-D a significant predictor of worse
outcome?
13. Effect size to two significant figures with +/- signs:
14. Confidence rating in effect size computation:
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Figure 1.
Exclusion of Studies

50 studies relevant to topic

5 excluded: lacked non typeD subsample or complete
type-D analysis

3 excluded: contained only
healthy patient samples

18 excluded: did not contain
selected outcome measures

5 excluded: overlapping
patient populations

1 excluded: no cardiac
events

4 excluded: no standard
deviations provided

5 studies analyzed for
MACE
(n=5)

5 studies analyzed for
QOL
(n=5)

4 studies analyzed for
biochemical markers
(n=4)
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Capstone Project Summary
A meta-analysis is a research method which takes all of the studies done on a
particular research topic and allows researchers to combine the results and to better
examine the nature of the area of investigation. Results are reported in terms of a
quantitative measure referred to as an effect size. This allows for an increased sample
size which means a meta-analysis has greater statistical power than individual studies. A
large quantity of primary research has been completed to examine whether there is a
relationship between Type-D personality and negative outcomes for heart disease
patients, but no meta-analysis has been completed in the area. The cardiovascular
patient populations that have been studied are those diagnosed with chronic heart
failure, coronary heart disease, peripheral artery disease or acute coronary syndrome,
were attending cardiovascular rehabilitation, underwent coronary artery bypass grafting
surgery or percutaneous coronary intervention (angioplasty), or experienced a
myocardial infarction (heart attack). It is for that reason I chose to complete a metaanalysis on this topic for my Capstone Project.
A person who exhibits Type-D personality experiences a high level of negative
emotions such as anger, sadness, and anxiety. In addition, they do not express their
emotions and are extremely socially reserved for fear of rejection by others. Screening
for Type-D personality is accomplished by a brief fourteen item psychometrically sound
self-survey questionnaire called the DS-14. The DS-14 presents statements such as “I am
often happy”, “I am often in a bad mood”, and “I often find myself worrying about
something”. Individuals completing the survey rank statements such as these on a scale
of 0-5 indicating the truth of the statement as it pertains to them. This method of
identification of Type-D personality has been shown to produce consistent results over
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time which is important because Type-D is a stable construct that remains constant in
individuals unlike depression, for example, which changes in severity and can disappear
as time progresses.
The first step of this research was to conduct a literature search using PsycInfo
and Pubmed as well as a backwards search through references of recent articles on the
topic, called an ancestral search, in order to obtain all the research that had been
completed to date on the topic. The most common theme among the articles was the
examination of whether Type-D personality in cardiovascular patients was associated
with: 1) higher incidences of major adverse cardiac events (MACE) which were described
as cardiac death, myocardial infarctions, coronary artery bypass grafting surgery, or
percutaneous coronary intervention (formerly referred to as an angioplasty), 2) poor
quality of life, or 3) higher levels of disease promoting pro-inflammatory and lower
levels of disease preventing anti-inflammatory cytokine levels. Separate analysis was
conducted for each outcome.
A list of criteria was established for the inclusion or exclusion of each study to
ensure that only studies done in a similar manner and with adequate data would be
included in the analysis. This reduced the total number of studies to five for the MACE
analysis, five for the quality of life analysis, and four for the biochemical markers
analysis. All of the studies were then coded. This involved the development of a coding
book detailing all of the variables within the study and options to classify each study
with respect to each of their characteristics. This allows for direct comparison of the
similarities and differences between the studies and helps identify sources of variation
between the studies which could affect the results. In order to ensure this was done

77
correctly, each study was coded by both myself and another masters level individual
trained using the coding manual.
Once all of the data were coded, they were passed to Dr. Glen Spielmans who is
a meta-analytic expert at Metropolitan State University in Minnesota. He calculated
effect sizes for each individual study and overall effect sizes for all related studies. He
also conducted significance testing and tests to determine the degree of variability
between studies. If studies are found to be heterogeneous, meaning there is more
variability between the individual studies than is due to sampling error alone,
moderators within the studies need to be identified as possible sources of that
variation.
The results indicated that cardiovascular patients with Type-D personality had
more than three times greater odds of experiencing a major adverse cardiac event
following diagnosis then non Type-D patients. The quality of life analysis was divided
into two separate effect sizes depending on whether the individual studies reported
quality of life with dichotomous data (does the patient have a poor quality of life or not)
or continuous data (to what degree is the patients’ quality of life impaired). The effect
size using dichotomous data was significant indicating that Type-D patients had more
than three times greater odds of experiencing an impaired quality of life than non TypeD patients. The effect size calculated using continuous data came extremely close to
being significant. The sample size for the calculation was small because four studies had
to be excluded due to omissions in their reported data. It is hypothesized that had these
studies been included and the sample size been larger, the relationship between Type-D
personality and quality of life may have reached significance for the continuous data as
well.
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There were multiple effect sizes calculated in the biochemical markers analysis
in order to observe the relationship between Type-D personality and levels of individual
chemicals as well as combinations of chemicals. IL-6 and TNF-α are pro-inflammatory
cytokines. When pro-inflammatory cytokines are elevated for sustained periods of time
they have a disease promoting effect. High sustained levels of TNF-α cause the release
of its soluble receptors, sTNFR-1 and sTNFR-2, into blood plasma. Consequently, these
are more accurate indicators of sustained elevated TNF-α levels than the presence of
TNF-α plasma levels alone. Elevated levels of these pro-inflammatory cytokines have
been demonstrated to predict mortality among cardiovascular patients. The results
show that Type-D patients are more likely than non Type-D patients to have elevated
levels of IL-6, sTNFR-1, and sTNFR-2. There were no differences found between the
patient groups with respect to TNF-α levels. However, when analysis was completed
using combined levels of TNF-α, sTNFR-1, and sTNFR-2 the elevation of these levels in
Type-D patients compared to non Type-D patients was nearly found to be significant.
Combination of the levels of all the pro-inflammatory chemicals was also nearly found
to be significantly higher in Type-D individuals.
IL-10 and IL-1ra are anti-inflammatory cytokines which have inhibitory effects
on the pro-inflammatory cytokines in order to regulate the inflammatory process and
prevent the excess inflammation that leads to disease. Significance was not reached, but
there was a trend towards lower levels of these chemicals in Type-D versus non Type-D
patients. Cortisol is a chemical with both inflammatory and anti-inflammatory
properties. Chronically elevated cortisol levels promote disease progression as well as
abdominal obesity which has been linked to high cholesterol and atherosclerosis. No

79
differences were found among cortisol levels between the Type-D and non Type-D
patient groups.
All of the biochemical marker analyses had small sample sizes as this is a
relatively new direction of research. Many of the obtained effect sizes bordered on, but
did not reach, significance. With such small sample sizes this suggests that there may
still be a relationship between levels of these chemicals and Type-D personality. Further
research in this area is needed to establish a definite relationship.
Variability between studies which was greater than that due to sampling error
alone was also found in the quality of life analysis using continuous data as well as many
of the biochemical analysis data. Because of this, differences between the studies that
could possibly affect the data needed to be considered. Quality of life was assessed with
a different measurement instrument in each of the quality of life studies that presented
their data in a continuous form. Though the aim of each of these tools was to assess
quality of life, they all did so in a different way. One was specific to the effect of chronic
heart failure on quality of life while the other two could be generalized to all patient
groups. One was very simple, basically a rating of how your current life compares to you
ideal life, while the other two assessed extremely detailed dimensions of quality of life
with specific questions. If the same quality of life measure had been used in all three
studies it is possible that there would be less variability between the studies. Also,
though each study used a patient population falling under the umbrella of
cardiovascular disease, each patient population differed in their specific diagnosis. One
study used patients generally in cardiac rehabilitation, one used myocardial infarction or
coronary artery bypass grafting surgery patients and the last used peripheral artery
disease patients. This could also account for variability between studies. Possible

80
sources for variation between studies in the biochemical marker analysis were
differences in average patient age and the inclusion of fourteen kidney dysfunction
patients within the Type-D group in one study. Both advancing age and kidney
dysfunction have been found to be sources of elevated levels of pro-inflammatory
cytokines.
The findings of this meta-analysis have some important implications. Not only
was Type-D personality found to be a powerful predictor of major adverse cardiac
events and poor quality of life in cardiovascular patients, but it is also strongly suggested
that it has links to disease promoting biochemicals that have been found to predict
mortality in this patient population. All of the primary research was conducted in a small
number of countries in Europe, primarily the Netherlands, by a concentrated group of
researchers. This study urges for a broader body of research to be completed in order to
draw more definite conclusions and allow for the results to be generalized to a more
expansive demographic.
The study also calls attention to the need for Type-D screening to be completed
on cardiovascular patients as this is a very high risk patient group, and the prevalence of
Type-D personality has been found to be about 20-39% in patient samples. It also
suggests that research be conducted to examine possible treatments to improve the
prognosis for Type-D individuals. Some suggested treatments are pharmacological with
anti-depressants to decrease the intensity of negative emotions, exercise, cognitive
behavioral therapy, social skills training and coping mechanisms. All of these treatments
aim to decrease emotional distress and increase social support. A definite association
has been established between Type-D personality and poor prognosis in this metaanalysis. This research should further call attention to the need for additional and
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specialized treatment to improve the survival of Type-D patients and, hopefully, in the
future will result in changes in the clinical environment to facilitate this high-risk patient
groups’ survival rates.

Table 1
Study Information Chart
Sample

Type-D Measurement

Construct Measured

Denollet et al.,
2000

Study

319 patients at Antewerp
Cardiac Rehabilitation
Center eligible if had myocardial infarction,
coronary artery bypass grafting surgery, or
percutaneous coronary
intervention within 2 months
of entering program
(Jan. 1989-Dec 1992)

DS-16

MACE: Cardiac Death,
Myocardial Infarction, Coronary
Artery Bypass Grafting Surgery,
Percutaneous Coronary Intervention

Effect Size
OR = 4.14

Pederson et al.,
2004

875 patients treated with percutaneous
coronary intervention as part of

DS-14

MACE: Cardiac Death,
Myocardial Infarction

OR = 4.47

Schiffer et al.,
2009

232 chronic heart failure outpatients
From cardiology unit of
Tweesteden teaching hospital

DS-14

MACE: Cardiac Death

OR = 2.16

Denollet et al.,
2006

337 chronic heart disease patients
participating in Antewerp
Cardiac Rehabilitation Center
(Jan. 1993-Dec. 1997)

DS-16

MACE: Cardiac Death,
Myocardial Infarction, Coronary
Artery Bypass Grafting Surgery,
Percutaneous Coronary Intervention

OR = 2.88

Denollet et al.,
1996

303 chronic heart disease patients
participatingin Antewerp
Cardiac Rehabilitation
Center (Jan 1985-Dec 1988)

State Trait Anxiety Inventory
(negative affectivity measure)
Social Inhibition Scale of the Heart
Patients Psychological
Questionnaire (social inhibition
measure)

MACE: Cardiac Death

OR = 4.98
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437 coronary artery bypass grafting surgery
patients who came in for annual
follow-up at Harefield Hospital

DS-14

QOL: SF-36

OR =3.63

368 patients referred to Rotterdam
Organization for Cardiac Rehabilitation

DS-14

QOL: SF-36

d = -.62

Schiffer et al.,
2005

84 systolic heart failure patients visiting
heart failure outpatient clinic at Tweesteden
teaching hospital

DS-14

QOL: Health Complaints Scale, MLWHFQ

OR = 2.86

Karlsson et al.,
2007

224 acute myocardial infarction or
coronary artery bypass grafting
surgery patients from Danderyd Hospital

DS-14

QOL: Cantril Ladder of Life

d = -2.2

Aquarius et al.,
2007

150 peripheral artery disease patients
from outpatient clinic
at St. Elisabeth Hospital

DS-14

QOL: WHOQOL

d = -.88

Denollet et al.,
2008

130 chronic heart failure patients from
outpatient heart failure
clinic at University Hospital of Antewerp

DS-14

Biochemical Markers:
TNF-α, sTNFR-1,
sTNFR-2, IL-6

d = -2.70

Denollet et al.,
2009

165 chronic heart failure outpatients from
Tweesteden teaching hospital

DS-14

Biochemical Markers:
TNF-α, sTNRF-1, sTNFR-2,
IL-6, IL-10, IL-1ra

d = -.51

Conraads et al.,
2006

91 chronic heart failure patients from
outpatient clinic of University
Department of Cardiology

DS-14

Biochemical Markers: TNF-α, sTNRF-1,
sTNRF-2, IL-6

d = -.57

Al-Ruzzeh et al.,
2005

Pelle et al.,
2008
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Whitehead et
al., 2007

72 acute coronary syndrome patients
recruited from four London hospitals

DS-16

Biochemical Markers:
Cortisol

d=-.24

*MACE: Major Adverse Cardiac Event
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Table 2
Summary of Statistical Data for Individual Analyses

k

n(Type-D)

n(non Type-D

OR

CI

Q

p(Q)

I

5

584

1482

3.42

2.48-4.73

<.001

3.27

.51

0%

2

188

333

3.48

2.37-5.11

<.001

.21

.65

0%

3

98

270

-1.23

2.61

.01

51.88

<.001

96.15%

IL-6

3

105

200

-.26

2.17

.03

.04

.98

0%

TNF-α

3

105

200

-1.07

1.38

.17

67.07

<.001

97.02%

sTNFR-1 +
sTNFR-2

3

105

200

-1.84

1.97

.05

81.97

<.001

97.56%

TNF-α, sTNFR-1
+ sTNFR-2

3

105

200

-1.58

1.80

.07

76.30

<.001

97.39%

IL-6 , TNF-α,
sTNFR-1 +
sTNFR-2

3

105

200

-1.10

1.84

.07

48.37

<.001

95.87%

IL-10 + IL-1ra

1

32

52

-.42

1.86

.06

Cortisol

1

23

43

-.24

.93

.35

MACE

a

QOL
(Dichotomous
Data)
QOL
(Continuous
Data)

d

Z

2

p(ES)

Construct
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a

MACE- Major Adverse Cardiac Event (Cardiac Death, MI, CABG, or PCI)

74

Table 3
Summary of Moderator Analysis Data
Included Studies

Excluded
Study

QOL: Aquarius et al.,
Pelle et al.,
2007 +
2008
Karlsson et al., 2007
QOL: Aquarius et al., Karlsson et al.,
2007 +
2007
Pelle et al., 2008
QOL: Karlsson et al., Aquarius et al.,
2007 +
2007
Pelle et al., 2008
Pro-inflammatory
Denollet et al.,
Cytokines:
2009
Conraads et al., 2006
+ Denollet et al., 2008

Moderators Tested For

d

Z

P(ES)

Q

P(Q)

I2

Longitudinal design
Patients underwent cardiac rehabilitation

-1.54

2.34

.019

26.01

<.001

96.16%

Different group of researchers
Simplistic and generalized QOL
measurement
Larger proportion of smokers
Smaller sample size

-.50

1.33

.18

12.24

<.001

91.83%

-1.16

1.13

.26

87.69

<.001

98.86%

-1.63

1.53

.13

37.28

<.001

97.32%

Higher proportion of patients NYHA III/IV
Longitudinal design
Greater mean age
Fourteen Type-D patients with kidney
dysfunction

67
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